News
-
-
PRESS RELEASE
Sandoz steps up in-house biosimilar capabilities, opening state-of-the-art development centre to capture ‘golden decade’ opportunity
Sandoz opens new biosimilar development centre in Ljubljana, Slovenia, to enhance in-house capabilities for upcoming biologic patent expiries. The state-of-the-art facility will support growth in the 'golden decade' of healthcare -
-
-
-
PRESS RELEASE
Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes
Sandoz Group AG confirms European Commission approval for biosimilars Bysumlog(R) (insulin lispro) and Dazparda(R) (insulin aspart), strengthening position in diabetes -
-
-
-
PRESS RELEASE
Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets
Sandoz signs agreement with Rwandan government to ensure stable provision of critical medicines in Africa. Strategic partnership for antibiotic and cancer therapies. Sandoz aims to provide affordable, high-quality medicines in the region
